Association of distinct clinical subsets with myositis-specific autoantibodies towards anti-155 140-kDa polypeptides, anti-140-kDa polypeptides, and anti-aminoacyl tRNA synthetases in Japanese patients with dermatomyositis: a single-centre, cross-sectional study

Objective: To determine the association of distinct clinical subsets with myositis-specific autoantibodies (MSAs) towards anti-155 140-kDa polypeptides [anti-155 140 antibodies (Abs)], anti-140-kDa polypeptides (anti-140 Abs), and anti-aminoacyl tRNA synthetases (ARS Abs) in Japanese patients with d...

Full description

Saved in:
Bibliographic Details
Published inScandinavian journal of rheumatology Vol. 38; no. 4; pp. 263 - 267
Main Authors Fujikawa, K., Kawakami, A., Kaji, K., Fujimoto, M., Kawashiri, S., Iwamoto, N., Aramaki, T., Ichinose, K., Tamai, M., Kamachi, M., Nakamura, H., Ida, H., Origuchi, T., Ishimoto, H., Mukae, H., Kuwana, M., Kohno, S., Takehara, K., Sato, S., Eguchi, K.
Format Journal Article
LanguageEnglish
Published Colchester Informa UK Ltd 2009
Taylor & Francis
Informa
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Objective: To determine the association of distinct clinical subsets with myositis-specific autoantibodies (MSAs) towards anti-155 140-kDa polypeptides [anti-155 140 antibodies (Abs)], anti-140-kDa polypeptides (anti-140 Abs), and anti-aminoacyl tRNA synthetases (ARS Abs) in Japanese patients with dermatomyositis (DM). Methods: We compared the clinical features and short-term prognoses of 30 DM patients whose serological status included these MSAs. The MSAs were determined by immunoprecipitation. Results: Anti-155 140 Abs (n = 5), anti-140 Abs (n = 8), and anti-ARS Abs (n = 7) did not overlap each other. All of the anti-155 140 Ab-positive patients (n = 5) were complicated by malignancies, as were all of the anti-140 Ab-positive patients (n = 8), who showed rapidly progressive interstitial lung disease (ILD). The survival rate at 6 months from the diagnosis of DM was significantly lower in the anti-140 Ab-positive patients than in the other patients. Conclusion: This is the first study to report, in a single cohort of DM patients, that distinct clinical subsets are distributed in an anti-155 140 Ab-positive group, an anti-140 Ab-positive group, or an anti-ARS Ab-positive group. Our data also confirm previous evidence that anti-155 140 Abs are involved in malignancies and that anti-140 Abs are involved in rapidly progressive ILD.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0300-9742
1502-7732
DOI:10.1080/03009740802687455